Bionano Genomics Announces Canadian College of Medical Geneticists Presentation Featuring Applications of OGM for Genetic Research
Bionano Genomics (BNGO) has announced a two-hour presentation on Optical Genome Mapping (OGM) technologies by researchers from leading institutions at the Canadian College of Medical Geneticists (CCMG) General Meeting 2022, scheduled from June 6-10.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bionano Genomics (BNGO) has announced a two-hour presentation on Optical Genome Mapping (OGM) technologies by researchers from leading institutions at the Canadian College of Medical Geneticists (CCMG) General Meeting 2022, scheduled from June 6-10. The workshop, titled New Technologies and Applications of Optical Genome Mapping, will take place on June 8, featuring esteemed presenters from Columbia University Medical Center and University Health Network. This highlights Bionano's commitment to advancing genomic research and applications related to prenatal testing and cancer diagnostics.
Positive
- Collaboration with prestigious institutions enhances reputation.
- Presentation at major conference indicates strong interest in OGM technologies.
Negative
- None.
Details
News Market Reaction – BNGO
The recorded move for BNGO in the trading session of this news was -3.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that researchers from University Health Network in Toronto, Columbia University Medical Center, and Children’s Hospital of Eastern Ontario will deliver a two-hour presentation on technologies and applications of OGM for genetic research at the Canadian College of Medical Geneticists (CCMG) General Meeting 2022. The CCMG conference will be held virtually this year and runs from June 6-10, 2022.
Details of the presentation:
Category: Workshop 2
Session Time: Wednesday, June 8, 2022 – 11:35A-1:35A (PST)
Title: New Technologies and Applications of Optical Genome Mapping
Presenters: Dr. Brynn Levy, Professor of Pathology and Cell Biology at Columbia University Medical Center, Dr. Adam Smith, Director of the Cancer Cytogenetics Laboratory at University Health Network, and Dr. Lijia Huang, Clinical Molecular Geneticist at Children’s Hospital of Eastern Ontario
For more details and to register for the conference, please visit https://hopin.com/events/ccmg-46th-annual-scientific-meeting/registration.
“We are pleased that researchers at University Health Network, Children’s Hospital of Eastern Ontario, and Columbia University Medical Center will be presenting at the CCMG conference on the pioneering research they are doing with OGM. Our customers continue to push forward cutting-edge applications in areas including prenatal testing and cancer diagnosis and we look forward to the authors sharing their research with the CCMG community. We thank Dr. Smith, Dr. Levy, and Dr. Huang for their commitment to OGM and we are impressed by their innovative drive,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.